5949-49-5

Basic information

• Product Name: (6beta)-6-hydroxyestr-4-ene-3,17-dione
• Synonyms: 6beta-Hydroxyestr-4-ene-3,17-dione; Estr-4-ene-3,17-dione, 6-hydroxy-, (6beta)-
• CAS NO: 5949-49-5
• Molecular Formula: C₁₈H₂₄O₃
• Molecular Weight: 288.3814
• Mol File: 5949-49-5.mol

Chemical Properties

• Boiling Point: 484°C at 760 mmHg
• Flash Point: 260.6°C
• Density: 1.21g/cm³
• Vapor Pressure: 2.13E-11mmHg at 25°C
• Refractive Index: 1.574
• CAS DataBase Reference: (6beta)-6-hydroxyestr-4-ene-3,17-dione(CAS DataBase Reference)
• NIST Chemistry Reference: (6beta)-6-hydroxyestr-4-ene-3,17-dione(5949-49-5)
• EPA Substance Registry System: (6beta)-6-hydroxyestr-4-ene-3,17-dione(5949-49-5)

Safety Data

• Hazardous Substances Data: 5949-49-5(Hazardous Substances Data)

Usage

Uses

Used in Hormone Replacement Therapy:
(6beta)-6-hydroxyestr-4-ene-3,17-dione is used as a hormone replacement agent for addressing menopausal symptoms. It helps alleviate symptoms such as hot flashes, night sweats, and vaginal dryness, providing relief and improving the quality of life for postmenopausal women.
Used in Orthopedics:
In the field of orthopedics, (6beta)-6-hydroxyestr-4-ene-3,17-dione is used as a treatment for osteoporosis. It helps in maintaining bone density and preventing bone loss, reducing the risk of fractures and improving overall bone health.
Used in Oncology:
(6beta)-6-hydroxyestr-4-ene-3,17-dione is used as a potential therapeutic agent for certain types of cancer. Its role in hormone regulation makes it a candidate for the treatment of hormone-sensitive cancers, such as breast and endometrial cancer. Further research is needed to fully understand its potential applications in oncology.
Used in Pharmaceutical Research:
(6beta)-6-hydroxyestr-4-ene-3,17-dione is also used as a subject of pharmaceutical research for the development of new drugs targeting hormone-related conditions. Its unique structure and biological activity make it a valuable compound for exploring novel therapeutic approaches and drug candidates.

Upstream product

• 434-22-0 19-nortestosterone 
• 734-32-7 estra-4-ene-3,17-dione 
• 70286-48-5 3-acetoxy-19-nor-androsta-3,5-dien-17-one 

Relevant articles and documents

NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I) : and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein-, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF

Provided herein are 3,3-disubstituted19-nor-steroidal compounds according to Formula(I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions,for example, treatment of sleep disorders, mood disorders,schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders,personality disorders,autism spectrum disorders, pain,traumatic brain injury, vascular diseases,substance abuse disorders and/or withdrawal syndromes, tinnitus, status epilepticus.

Transformations of 4- and 17α-substituted testosterone analogues by Fusarium culmorum

A series of 4- and/or 17α-substituted testosterone analogues has been incubated with the hydroxylating fungus Fusarium culmorum AM282. It was found that 19-norandrostenedione, 19-nortestosterone, 4-methoxytestosterone, 4-methyltestosterone, and 4-chloro-17α-methyltestosterone were hydroxylated exclusively or mainly at the 6β-position. The mixtures of 6β-, 15α-, and 12β- or 11α-monohydroxy derivatives were obtained from 17α-methyltestosterone and 17α-ethyl-19- nortestosterone - the substrates with alkyl group at C-17α. 4-Chlorotestosterone was predominantly hydroxylated at 15α-position, but the reaction was accompanied by the reduction of 4-en-3-one system, which proceeded in the sequence: reduction of ketone to 3β-alcohol and then reduction of the double 4,5 bond. The results obtained indicate an influence of stereoelectronic and steric effects of substitutes on regioselectivity of the hydroxylation of 4-en-3-one steroids by F. culmorum.